Biomarker Ratio Imaging for Precise DCIS Aggressiveness Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately stratify the aggressiveness of ductal carcinoma in situ (DCIS) lesions, leading to over-treatment of non-aggressive forms and under-treatment of aggressive forms, as existing techniques lack precision in prognostic insight.
Innovation Solution
Biomarker ratio imaging microscopy (BRIM) is employed to analyze biomarker pairs such as CD44/CD24, N-cadherin/E-cadherin, CD74/CD59, using fluorescence imaging to generate high-contrast images that reflect tumor aggressiveness by dividing the expression of positively correlated biomarkers by negatively correlated biomarkers, thereby overcoming optical artifacts due to variations in sample thickness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging techniques are used to evaluate DCIS lesions, then the diagnostic process is simple, but the precision of stratifying aggressiveness is insufficient
Solution Approach 1:
The patent segments the evaluation process into multiple distinct steps: (1) obtaining a tissue section, (2) labeling with multiple fluorescently-conjugated antibodies targeting different biomarkers, (3) acquiring separate fluorescent images for each biomarker, and (4) computing ratio images by dividing numerator biomarker intensity by denominator biomarker intensity. This segmentation allows complex multi-biomarker analysis to be performed systematically, improving measurement precision while managing device complexity through structured methodology
Solution Approach 2:
The patent transforms the evaluation from measuring single biomarker levels to computing ratio parameters (numerator biomarker/denominator biomarker). This parameter transformation enables the system to overcome optical artifacts related to sample thickness and labeling efficiency variations, as the ratio cancels out common multiplicative factors. The parameter change from absolute intensity to relative ratio directly improves measurement precision for aggressiveness stratification
2Loss of information
If single biomarker analysis is performed, then the methodology is straightforward, but the ability to characterize tumor aggressiveness is limited
Solution Approach 1:
The patent merges multiple biomarker analyses into a unified ratio-based evaluation system. By selecting numerator biomarkers positively correlated with aggressiveness and denominator biomarkers negatively correlated, the system combines information from multiple biological pathways into a single integrative metric. This merging preserves comprehensive information about tumor aggressiveness while simplifying the interpretation through a unified ratio parameter
Solution Approach 2:
The ratio computation acts as an intermediary that transforms complex multi-biomarker data into a clinically interpretable metric. The ratio image serves as an intermediate representation that encodes aggressiveness information while being resistant to technical variations. This intermediary layer bridges the gap between complex molecular biology and clinical decision-making, reducing information loss
3Measurement precision
If fluorescent labeling with multiple antibodies is used, then biomarker detection sensitivity is improved, but optical artifacts due to sample thickness variations increase
Solution Approach 1:
The patent changes the measurement parameter from absolute fluorescent intensity to relative intensity ratio. By computing the ratio of numerator biomarker intensity to denominator biomarker intensity at each pixel location, the system cancels out optical artifacts that affect both biomarkers equally (such as sample thickness variations, excitation light intensity variations, and detector sensitivity variations). This parameter transformation maintains detection sensitivity while eliminating the harmful optical artifacts
Solution Approach 2:
The denominator biomarker serves as a counterweight that compensates for optical artifacts affecting the numerator biomarker. Since both biomarkers are measured in the same tissue section under identical imaging conditions, variations in sample thickness and optical path affect both labels proportionally. The ratio computation uses the denominator as a reference to counterbalance these artifacts, isolating the true biological signal related to tumor aggressiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the precise stratification of DCIS lesions, enabling the precise characterization of ductal carcinoma in situ (DCIS) and the precise characterization of ductal carcinoma in situ (DCIS) lesions, thereby improving standardization and efficacy.
Implementation Method 1
Each biomarker to be quantitated is labeled with a separately optically-detectable label. In some embodiments, the optically-detectable labels are fluorescent dyes.
Implementation Method 2
quantitating the level of the first and second biomarkers by detecting the first and second detection reagents using fluorescence imaging microscopy
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 2A~2E
AI summary
Provided herein are methods and systems for the analysis of biomarkers, and methods of providing diagnoses and/or prognoses therewith. In particular, methods and systems for performing biomarker ratio imaging microscopy (BRIM) are provided, as well as methods of using BRIM for the analysis of biomarker pairs (e.g., CD44/CD24, N-cadherin/E-cadherin, CD74/CD59, etc.) diagnosis and/or prognosis of cancer (e.g., ductal carcinoma in situ).